BIO 2015 Dispatches: Acorda CEO Cohen To Bring 'Passion' To BIO Chairmanship
This article was originally published in The Pink Sheet Daily
Executive Summary
Congenial Acorda CEO Ron Cohen is chosen to lead the industry group during the upcoming year as the biotech industry gathers in Philadelphia for BIO's annual conference.
You may also be interested in...
Ampyra Approval: Acorda's Lessons Learned
There are many factors that contributed to Acorda's success in gaining approval for Ampyra (dalfampridine), but looking back at the process, CEO Ron Cohen and Chief Scientific Officer Andy Blight agree that the biggest asset was having a Special Protocol Assessment for the Phase III trials.
Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race
Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.
Novo Mulls What To Do With Wegovy Windfall
The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.